Navigation Links
Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method

CAMBRIDGE, Mass., May 8, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals today announced that the United States Patent and Trademark Office has issued patent number 8,168,755 entitled, "Antibodies specific to heterodimers of Bcl-2 family and uses thereof."

The patent provides a novel method for extending Eutropics' BH3 profiling technology, which is exclusively licensed from the Dana Farber Cancer Institute. This technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to know ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs. This new invention by Eutropics provides a method for extending utility of the technology within solid tumors.

Eutropics is currently involved in the commercialization of the BH3 profiling assay. The test is being developed for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients as well as solid cancers. This work is being done in collaboration with the Dana Farber Cancer Institute, UMass Worcester Medical School, MD Anderson Cancer Center, and the NCI/NIH.

Michael Cardone, Co-Founder and CEO of Eutropics commented, "We are very pleased with the progress being made toward the commercial development of BH3 profiling at Eutropics. Gaining protection on this new intellectual property will help extend the process into a broader range of oncology indications. The company has made excellent progress in our clinical studies and is working very hard to provide a tool to help physicians acquire this diagnostic test that will help guide the use of chemotherapies, ultimately leading to better patient outcomes."

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by guiding the use of novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology. This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.

SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... A long-standing partnership between the Academy of ... formalized with the signing of a Memorandum of Understanding. , AMA Executive Director ... Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters in ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
Breaking Biology Technology:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
Breaking Biology News(10 mins):